Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
January 05 2024 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the appointment of
Adam Laponis as chief financial officer. Mr. Laponis brings
experience across small cap and Fortune 50 companies along with a
track record of collaborating across teams to drive profitable
growth.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240105333128/en/
Adam Laponis, chief financial officer of
Twist Bioscience (Photo: Business Wire)
“Adam’s deep financial acumen and strategic planning expertise
across diverse businesses make him an ideal fit for our next phase
of growth,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist Bioscience. “His wide-ranging experience within large pharma
and their business units, automobile manufacturers and start-up
organizations will provide valuable insights as we scale the
business, remaining laser focused on driving toward profitability
and expanding gross margin while serving our customers and enabling
them to conduct breakthrough research.”
“Throughout my career I have been drawn to mission-driven
companies, and I’m particularly excited to join Twist at this
pivotal time as the company is moving toward cash flow breakeven,”
said Mr. Laponis. “Twist’s ability to manufacture DNA at an
unprecedented scale and speed is truly enabling positive
developments in health, food security and sustainability. I look
forward to working with the talented and experienced team and I’m
committed to using my expertise and skillset to drive value for all
of our stakeholders.”
Mr. Laponis joins Twist from Eargo, Inc., where he served as
chief financial officer, responsible for finance, accounting,
investor relations, business operations, internal audit and
information technology. During his tenure at Eargo, revenue
increased more than 300% over the course of two years. Prior to
Eargo, Mr. Laponis was vice president, worldwide financial planning
and analysis and business operations at Tesla, Inc. where he was
responsible for worldwide pricing, forecasting, capital planning,
development of internal controls, and optimization of business
operations. Previously, Mr. Laponis served as vice president,
finance and chief financial officer, cardiovascular care at
Cardinal Health as the finance leader for the worldwide Cordis
Cardiovascular business. He held a series of roles of increasing
responsibility at Johnson & Johnson, where he led the
divestiture of Cordis to Cardinal Health. He held additional
positions within Johnson & Johnson including controller of the
diabetes franchise, manager of supply chain and quality finance and
customer service finance. Mr. Laponis holds an MBA from the
University of Southern California, Marshall School of Business and
a B.S. in chemical engineering from the University of California at
Berkeley.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding Twist
Bioscience’s future growth and expansion, and ability to achieve
profitability and increase gross margin. Forward-looking statements
involve known and unknown risks, uncertainties, and other important
factors that may cause Twist Bioscience’s actual results,
performance, or achievements to be materially different from any
future results, performance, or achievements expressed or implied
by the forward-looking statements. Such risks and uncertainties
include, among others, the ability to achieve the expected benefits
of Twist Bioscience’s restructuring activities and reduced
investments in DNA data storage; the ability to attract new
customers and retain and grow sales from existing customers; the
ability of Twist Bioscience to achieve sufficient revenue to
achieve or maintain positive cash flow from operations or
profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission on November 21,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105333128/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Generalist
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024